A Deal For Biogen, But Not The One Investors Are Waiting For
The firm announced a small deal with Karyopharm for a preclinical asset with potential in ALS, but large deals are also being considered, management told the fourth quarter earnings call.
You may also be interested in...
Deal Watch: Iktos Doubles Its 2022 Alliance Tally In Agreements With Galapagos, Zealand
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
TMS Stroke Deal Suggests No Big Buy From Biogen Yet
The investment community has been willing Biogen to make a big deal for some time now but a modest pact inked with Japan's TMS for its Phase II acute ischemic stroke drug suggests that management will continue to favor picking up promising compounds rather than diving into major M&A.
Biogen's Spinraza Sales Plateau; The Challenge Is Keeping Up With The Successful Launch
Sales of Biogen's blockbuster rare disease drug moderated in the first quarter as the company worked through the bolus of urgent infant and pediatric patients awaiting treatment in the US.